| 51 |
33881797 | Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. | 2021 Aug |
2 |
| 52 |
33926446 | The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial. | 2021 Apr 29 |
1 |
| 53 |
33931817 | Buried Kex2 Sites in Glargine Precursor Aggregates Prevent Its Intracellular Processing in Pichia pastoris Muts Strains and the Effect of Methanol-Feeding Strategy and Induction Temperature on Glargine Precursor Production Parameters. | 2021 Sep |
6 |
| 54 |
33938149 | Comparative clinical outcomes of insulin degludec and insulin glargine 300 U/mL after switching from other basal insulins in real-world patients with type 1 and type 2 diabetes. | 2021 Nov |
1 |
| 55 |
33953588 | Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus. | 2021 |
4 |
| 56 |
34002663 | Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes. | 2021 May 18 |
2 |
| 57 |
34003539 | Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience. | 2021 Sep |
1 |
| 58 |
34027219 | Clinical research of insulin glargine U300 in type 1 diabetes mellitus patients with frequent hypoglycaemia: real-world experience. | 2021 |
3 |
| 59 |
34047960 | Clinical Characteristics of Withdrawal of Basal Insulin Therapy Among Japanese Patients with Type 2 Diabetes: A Multicenter Retrospective Observational Study. | 2021 Jul |
1 |
| 60 |
34052987 | Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study. | 2021 Jul |
3 |
| 61 |
34075142 | A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care. | 2021 Jun 1 |
2 |
| 62 |
34078438 | Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine. | 2021 Jun 2 |
2 |
| 63 |
34121308 | Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus®) in Chinese patients with type 1 diabetes: A phase III, randomized, controlled trial. | 2021 Oct |
3 |
| 64 |
34133466 | Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine. | 2021 |
11 |
| 65 |
34160790 | Clinical Benefit of Insulin Glargine 300 U/mL Among Patients with Type 2 Diabetes Mellitus Previously Uncontrolled on Basal or Premixed Insulin in Serbia: A Prospective, Observational, Single-Arm, Multicenter, Real-World Study. | 2021 Jul |
1 |
| 66 |
34174848 | Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies. | 2021 Jun 26 |
4 |
| 67 |
34180955 | Changes Associated With the Entry of a Biosimilar in the Insulin Glargine Market. | 2021 Oct 1 |
1 |
| 68 |
34211933 | Comparison of the effect of insulin glargine and regular insulin on perioperative glycemic control in patients with type 2 diabetes mellitus under insulin treatment during vitrectomy surgery under general anesthesia: A randomized clinical trial study. | 2021 |
5 |
| 69 |
34249838 | The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. | 2021 |
2 |
| 70 |
34299526 | NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products. | 2021 Jul 13 |
1 |
| 71 |
34305809 | Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial. | 2021 |
1 |
| 72 |
34322967 | Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. | 2021 Nov |
2 |
| 73 |
34337072 | Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial. | 2021 |
4 |
| 74 |
34345540 | Safety and Efficacy of Long-Acting Insulins Degludec and Glargine Among Asian Patients With Type 2 Diabetes Mellitus: A Meta-Analysis. | 2021 Jun |
5 |
| 75 |
34357560 | Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes. | 2021 Sep |
1 |
| 76 |
34393250 | [Adrenal cavernous hemangioma: A case report and literature review]. | 2021 Aug 18 |
1 |
| 77 |
34410042 | A Euglycemic Glucose Clamp Study to Evaluate the Bioavailability of LY2963016 Relative to Insulin Glargine in Healthy Chinese Subjects. | 2021 Dec |
2 |
| 78 |
34467826 | Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update. | 2021 Nov |
2 |
| 79 |
34472693 | Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial. | 2021 Dec |
2 |
| 80 |
34481498 | Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. | 2021 Sep 4 |
1 |
| 81 |
34580638 | Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study. | 2021 |
4 |
| 82 |
34594103 | Molecular Modeling and Bioinformatics Analysis of Drug-Receptor Interactions in the System Formed by Glargine, Its Metabolite M1, the Insulin Receptor, and the IGF1 Receptor. | 2021 |
1 |
| 83 |
34599749 | Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study. | 2021 Nov |
1 |
| 84 |
34636912 | Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. | 2021 Oct 1 |
2 |
| 85 |
34672967 | Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. | 2021 Nov 13 |
1 |
| 86 |
34672968 | Surpassing insulin glargine in type 2 diabetes with tirzepatide. | 2021 Nov 13 |
1 |
| 87 |
34676266 | Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. | 2021 |
2 |
| 88 |
34763587 | Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. | 2021 Jan-Dec |
2 |
| 89 |
34815261 | Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. | 2021 Oct-Dec |
1 |
| 90 |
34852652 | Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars. | 2021 Dec 1 |
5 |
| 91 |
34904015 | Comparison of Insulin Glargine and Detemir Effects on Hormones of Appetite and Metabolic Control in Patients with Type 1 Diabetes: A Randomized Clinical Trial. | 2021 Summer |
1 |
| 92 |
34917025 | Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring. | 2021 |
2 |
| 93 |
34917687 | Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice. | 2021 |
3 |
| 94 |
34925042 | Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study. | 2021 |
1 |
| 95 |
34956518 | Clinical effects of insulin glargine combined with repaglinide in the treatment of type 2 diabetes. | 2021 |
4 |
| 96 |
34971335 | The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn. | 2021 Dec 31 |
7 |
| 97 |
31150327 | Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes. | 2020 Feb |
4 |
| 98 |
31288531 | In Silico Examination of Initiation of Long-Acting Insulin Analogs Toujeo Compared to Lantus Under 3 Dosing Titration Rules in Virtual Type 2 Diabetes Subjects. | 2020 Sep |
1 |
| 99 |
31342163 | Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study. | 2020 Jan |
1 |
| 100 |
31365765 | Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. | 2020 Feb |
2 |